Antimicrobial Drugs and Mechanisms of Action

Antimicrobial drugs are agents that kill or inhibit the growth of microorganisms, and the class is organised by the bacterial process each agent targets: cell-wall synthesis, protein synthesis, nucleic-acid synthesis, or folate metabolism. Their selective toxicity — harming the pathogen while sparing the host — is the defining principle of the class, and the rise of resistance is its central modern challenge.

Definition

Antimicrobial (anti-infective) drugs are agents that selectively inhibit or kill microorganisms by acting on targets essential to the pathogen but absent or sufficiently different in the host, and are classified by their mechanism of action — inhibition of cell-wall synthesis, protein synthesis, nucleic-acid synthesis, or folate metabolism.

Scope

This topic covers the major mechanistic categories of antibacterial agents, the molecular targets that distinguish them, the concept of selective toxicity, and the principal mechanisms by which bacteria become resistant. It treats antimicrobials as a pharmacological class within the basis of major drug classes; it is reference and educational, not a prescribing or stewardship protocol, and contains no dosing guidance.

Core questions

• How does selective toxicity allow an antimicrobial to harm the pathogen while sparing the host?
• What are the principal molecular targets that define the major antibacterial classes?
• How do bactericidal and bacteriostatic actions differ mechanistically?
• By what molecular mechanisms do bacteria acquire and spread resistance to each class?

Key concepts

• Selective toxicity
• Cell-wall synthesis inhibitors (beta-lactams, glycopeptides)
• Protein synthesis inhibitors (aminoglycosides, macrolides, tetracyclines)
• Nucleic-acid synthesis inhibitors (fluoroquinolones, rifamycins)
• Folate pathway inhibitors (sulfonamides, trimethoprim)
• Bactericidal versus bacteriostatic action
• Antimicrobial resistance mechanisms
• Spectrum of activity

Key theories

Selective toxicity

Effective antimicrobials exploit biochemical differences between microbe and host — such as the bacterial cell wall, the 70S ribosome, or bacterial DNA gyrase — so that a target essential to the pathogen is absent or sufficiently different in human cells, giving the agent a therapeutic window.

Mechanisms

Antibacterial classes are defined by the essential bacterial process they disrupt. Beta-lactams and glycopeptides inhibit peptidoglycan cell-wall synthesis; aminoglycosides, tetracyclines, and macrolides bind the bacterial ribosome to block protein synthesis; fluoroquinolones inhibit DNA gyrase and topoisomerase IV to disrupt DNA replication, while rifamycins inhibit bacterial RNA polymerase; and sulfonamides with trimethoprim sequentially block folate synthesis required for nucleotide production. Because these targets are essential to the bacterium and absent or distinct in the host, the agents achieve selective toxicity. Resistance arises through enzymatic drug inactivation (for example beta-lactamases), target-site alteration or protection (as with gyrase mutations), reduced uptake, and active efflux, and these mechanisms can spread on mobile genetic elements.

Clinical relevance

Knowing the mechanism of an antimicrobial class predicts its spectrum, its characteristic adverse effects, and the resistance mechanisms it must overcome, which underpins evidence appraisal and antimicrobial-stewardship education. This entry describes how the agents act and how resistance emerges as a reference framework; it does not provide regimen selection, dosing, or individualised treatment advice.

Epidemiology

Antimicrobial resistance is a major global public-health concern, driven by the selection pressure of antimicrobial use across human medicine, agriculture, and the environment; resistance can disseminate rapidly through horizontal gene transfer, and surveillance of resistance mechanisms is central to controlling its spread.

Evidence & guidelines

Mechanistic classification of antimicrobials is codified in standard pharmacology texts, while resistance mechanisms and their drivers are synthesised in reviews such as Blair et al. (2015) and Holmes et al. (2016). Clinical use is governed by infection-specific guidelines and stewardship programmes that fall outside this reference entry.

History

The modern antimicrobial era began with the sulfonamides in the 1930s and the clinical introduction of penicillin in the 1940s, followed by the streptomycin and broad-spectrum-antibiotic discoveries that established the major mechanistic classes. Almost from the outset, the emergence of resistance accompanied clinical use, and the molecular dissection of resistance mechanisms has since become a defining theme of the field.

Debates

How best to slow the spread of antimicrobial resistance

Resistance is driven by selection pressure across human, agricultural, and environmental use, and there is ongoing debate over how stewardship, surveillance, and new drug development should be balanced to preserve the effectiveness of existing classes.

Key figures

• Alexander Fleming
• Gerhard Domagk
• Selman Waksman
• Laura Piddock

Seminal works

• blair-2015
• holmes-2016
• ruiz-2003

Frequently asked questions

What is the difference between bactericidal and bacteriostatic antibiotics?

Bactericidal agents kill bacteria directly, whereas bacteriostatic agents inhibit their growth and rely on host defences to clear the infection; the distinction depends on the target and the concentration achieved, and its clinical importance varies by setting.

Why do bacteria become resistant to antibiotics?

Resistance arises through mechanisms such as enzymatic inactivation of the drug, alteration or protection of the drug target, reduced uptake, and active efflux; these traits can be selected by antimicrobial use and spread between bacteria on mobile genetic elements.